Deepfakes, which usually involve superimposing someone’s face and voice onto another person, started gaining attention a few years ago when adult websites began banning videos where the technique was used to add famous actresses’ faces to porn stars’ bodies.
Advancing Novel Therapeutic Interventions For Unmet Medical Needs — Dr. Michael Hufford, Ph.D., Co-Founder and CEO, LyGenesis; Interim CEO, Morphoceuticals; Scientific Advisor, Juvenescence.
Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis (https://www.lygenesis.com/), a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He also serves as the Interim CEO of Morphoceuticals (https://www.morphoceuticals.com/) a company focused on modifying electric potentials in cells and tissues for a variety of applications in regenerative medicine, from improving amputation stump health and limb regeneration, to organogenesis, to creating a bioelectric atlas where numerous disease indications may be corrected.
Dr. Hufford also serves as a scientific advisor to Juvenescence (https://juvlabs.com/) a biotech holding company that develops therapies and products to modify aging and help people live longer.
An entrepreneur and drug developer, Dr. Hufford has over 20 years of experience in the development and FDA regulatory approval of small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has designed and executed clinical trials and drug development programs across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatric and oncology indications. His experience in-and out-licensing pre-clinical and clinical stage assets, executing corporate partnering deals, and in investor relations, has helped him to raise public, private, and angel-back financing for his companies. His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, Inc. (https://www.harmreductiontherapeutics.org/), a nonprofit pharmaceutical company developing low-cost over-the-counter intra-nasal naloxone in the US to help prevent opioid overdose deaths.
Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master’s and doctoral degrees in Clinical Psychology from the University of Pittsburgh, before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is an award-winning lecturer, and the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.
The patients had some, although severely diminished, visual function during the day, however, at night they were essentially blind, with light sensitivity 10,000–100,000 times less than normal.
According to researchers at the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania, adults with a genetic form of childhood-onset blindness experienced remarkable recoveries of night vision within days of receiving an experimental gene therapy.
The patients had Leber Congenital Amaurosis (LCA), a congenital blindness caused by GUCY2D gene mutations. The findings were published in the journal iScience. The researchers administered AAV gene therapy, which contains the DNA.
A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.
The Weill Cornell Medicine CAP-IT Center for LNP RNA Immunoprevention was selected as one of two founding members of the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT), a collaborative research network funded by the NCI to discover agents that prevent or intercept cancer in high-risk populations.
The maniacally focused founder of Insilico Medicine is going all in on AI to discover new medicines and extend lifespan.
But researchers are now using artificial intelligence to accelerate parts of that process by orders of magnitude. The same kind of technology that recognizes your face or autocompletes your emails can potentially add years to your life, experts say.
It could decrease reliance on palm oil to produce biofuel. Have you ever guessed that a leftover coffee could turn into biodiesel? Here’s a remarkable development for bioscience.
High quality biodiesel produced from microalgae ‘fed’ on leftover coffee grounds
Breakthrough in the microalgal cultivation system
Could decrease reliance on palm oil to produce biofuel.